Financial Performance Overview

Astec LifeSciences reported significantly improved financial results for FY 2025-26. The company achieved a consolidated net loss of ₹80.9 crore, a substantial improvement from the ₹134.7 crore loss in the previous year. This improvement was driven by a 17.1% increase in total income to ₹453.2 crore. The company reached EBITDA break-even with a positive EBITDA of ₹0.54 crore compared to an EBITDA loss of ₹(60.58) crore in FY25. Revenue was split between Contract Development and Manufacturing (CDMO) at 52% and Enterprise (generic actives) at 48%, with exports constituting 62% of total revenue.

Capital Structure and Corporate Actions

The company completed a Rights Issue in July 2025, issuing 26,69,951 equity shares at ₹890 per share and raising approximately ₹249.35 crore. The proceeds were utilized for repayment of borrowings and general corporate purposes, resulting in reduced total borrowings of ₹448.93 crore (from ₹554.54 crore in FY25). The debt equity ratio improved to 1.15 from 2.37 in the previous year. Godrej Agrovet Limited remains the holding company with 67.03% shareholding.

Management and Governance Changes

Significant management changes occurred in April 2026, with Mr. Burjis N. Godrej stepping down as Managing Director and being appointed as a Non-Executive Director. Mr. Vishal Sharma was appointed as Non-Executive Chairperson, and Mr. Arijit Mukherjee was appointed as Executive Director & COO. The company will hold its 32nd Annual General Meeting virtually on July 31, 2026, to adopt financial statements and seek shareholder approval for director re-appointment and cost auditor remuneration ratification.

ESG and Operational Metrics

The BRSR report provided comprehensive environmental, social, and governance metrics. Energy consumption totaled 487,119 MJ with 26.7% from renewable sources. Water withdrawal was 179,929 KL, while GHG emissions reached 42,021 tCO2e. The company maintained 100% coverage under Provident Fund and Gratuity benefits for its 307 permanent employees and 164 permanent workers. The lost time injury frequency rate was 0 for employees and 0.50 for workers.

Contingent Liabilities and Compliance

Significant contingent liabilities exist, including excise duty demands of ₹132.03 crore, GST demands of ₹8.26 crore, and customs matters of ₹0.41 crore, all under dispute with authorities. The company received an unmodified audit opinion from B S R & Co. LLP, with revenue recognition identified as a key audit matter. ICRA reaffirmed the company's ratings at [ICRA]AA- (Negative) for long-term facilities and [ICRA]A1+ for short-term facilities.

Related Party Transactions and Subsidiaries

Substantial transactions occurred with holding company Godrej Agrovet Limited, including sales of ₹27.10 crore and purchases of ₹17.51 crore. The company maintains subsidiaries including Behram Chemicals Private Limited (65.63% ownership) for agrochemical manufacturing and Comercializadora Agricola Agroastrachem Cia Ltda (100% ownership) for distribution in Colombia.

Compliance and Signatories

The financial statements comply with Indian Accounting Standards (Ind AS) and the Companies Act, 2013. The documents were signed by Arijit Mukherjee (Executive Director & COO), Sunil Kataria (Director), Deepak Ochani (CFO), and Tejashree Pradhan (Company Secretary & Compliance Officer), with auditing conducted by B S R & Co. LLP.